Another Fidelis dismissal
This article was originally published in The Gray Sheet
Executive Summary
Minnesota state judge dismisses more than 600 personal injury suits, including 14 distinct liability claims, against Medtronic related to its discontinued 7-French Sprint Fidelis defibrillator lead. The Oct. 20 dismissal 1order cites federal pre-emption protection for the FDA-approved product and follows a similar ruling in January in federal multi-district litigation (2"The Gray Sheet" Jan. 12, 2009). In both cases, the judges rejected plaintiffs' arguments that their claims were "parallel" to rather than in addition to FDA requirements and that the Class I recall of Fidelis invalidated its PMA supplement approval. Legislation to reverse the 2008 U.S. Supreme Court decision that forms the basis of these rulings is still pending in Congress (3"The Gray Sheet" Aug. 10, 2009)
You may also be interested in...
Senate Dems Argue That Device Safety Act Will Not Curb Innovation
Senate Democrats are challenging the notion that removing federal pre-emption protection for PMA-approved devices, solidified last year by the Supreme Court, will stifle innovation
Judge Wields Pre-emption To Dismiss Medtronic Fidelis Claims
A Minnesota federal judge on Jan. 5 categorically 1dismissed on grounds of federal pre-emption all 21 claims in a multidistrict personal injury lawsuit against Medtronic for its Sprint Fidelis implantable defibrillator leads
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.